Nathan Dowden Sells 3,116 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan Dowden sold 3,116 shares of the stock in a transaction on Monday, March 9th. The shares were sold at an average price of $13.02, for a total value of $40,570.32. Following the sale, the chief operating officer directly owned 210,482 shares in the company, valued at $2,740,475.64. This trade represents a 1.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Entrada Therapeutics Trading Up 0.7%

Shares of TRDA traded up $0.09 during trading hours on Friday, hitting $13.07. The company had a trading volume of 10,081 shares, compared to its average volume of 230,838. The company has a market capitalization of $500.32 million, a PE ratio of -3.78 and a beta of -0.12. Entrada Therapeutics, Inc. has a one year low of $4.93 and a one year high of $13.65. The company’s fifty day moving average price is $11.28 and its two-hundred day moving average price is $8.89.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Wall Street Analyst Weigh In

TRDA has been the topic of a number of analyst reports. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Oppenheimer assumed coverage on Entrada Therapeutics in a report on Wednesday, January 28th. They set an “outperform” rating and a $21.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Entrada Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

Hedge Funds Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TRDA. Allspring Global Investments Holdings LLC grew its stake in Entrada Therapeutics by 9.8% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after purchasing an additional 1,560 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Entrada Therapeutics by 7.1% in the third quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after purchasing an additional 1,620 shares during the period. Great Lakes Advisors LLC raised its stake in shares of Entrada Therapeutics by 5.5% in the fourth quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock worth $445,000 after purchasing an additional 2,239 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after purchasing an additional 2,397 shares during the period. Finally, Quadrature Capital Ltd lifted its holdings in shares of Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after purchasing an additional 2,424 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.